Project Grant R01AI202713
Award Date 8/3/26
Completion Date 7/31/31
Dollars Obligated $1.3M
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Boston, MA 02215, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases awarded $490,704 to the Trustees of Tufts College (doing business as Tufts University School of Medicine) on February 10, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop spatial multi-omics methodology predicting granuloma trajectory and bacterial restriction during tuberculosis vaccination. The recipient will use spatial proteomic and transcriptional profiling to map immune cell infiltrates in...
- The National Institute of Allergy and Infectious Diseases awarded Boston Medical Center Corporation $872,596 on April 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct research on HIV-1 antibody responses in people living with HIV who have tuberculosis and other opportunistic coinfections. The research examines how tuberculosis changes both the HIV-1 immune response and the characteristics of circulating viruses in coinfected individuals. The project...
- The National Institute of Allergy and Infectious Diseases awarded The University of Chicago $1,229,998 on August 14, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop a novel TH17-inducing mucosal tuberculosis vaccine. The research advances preclinical development of NETB-EA, a nanoemulsion-based vaccine candidate that delivers immunodominant Mycobacterium tuberculosis antigens (AG85B and ESAT6) via intranasal vaccination to induce T helper type 17 cell...
- The National Institute of Allergy and Infectious Diseases awarded The University of Chicago $810,282 on August 4, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate combination adjuvants that target trained immunity and the TH1/TH17 immune axis to enhance vaccine efficacy against tuberculosis and other infectious diseases. The research addresses the variable protective efficacy of the currently licensed TB vaccine, Mycobacterium bovis BCG (0–80%...
- Federal Project Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded Boston Children's Hospital $489,500 under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop innovative human cellular models for studying tuberculosis (TB) infection and innate immune responses. The award, effective August 1, 2025, through July 31, 2027, funds the establishment of a physiological in vitro lung alveolar epithelial cell organoid model derived...
- The National Institute of Allergy and Infectious Diseases awarded Seattle Children's Research Institute $1,033,950 on August 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop a tuberculosis vaccine regimen optimized to induce lung-resident T cells. The project, titled "A Prime-Pull TB Vaccine Regimen Optimized to Induce Lung-Resident T Cells," focuses on identifying and testing mRNA-lipid nanoparticle vaccine candidates designed to generate...
- The National Institute of Allergy and Infectious Diseases awarded Massachusetts General Hospital $798,107 on February 3, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to establish a tissue-based understanding of tuberculosis-associated lung fibrosis and post-TB lung disease pathology. The project creates a baseline understanding of molecules and cells driving fibrogenesis during TB infection, with the goal of identifying adjunctive therapies to modulate tissue...
- The National Institute of Allergy and Infectious Diseases awarded Brigham & Women's Hospital Inc. $194,400 on September 12, 2025, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct a five-year research career development program investigating antibody-dependent innate effector function in tuberculosis disease progression among HIV co-infected individuals. The research will apply expanded effector functional profiling to evaluate how HIV alters the breadth...
- The National Institute of Allergy and Infectious Diseases awarded Boston Medical Center Corporation $795,622 on May 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate mycobacterium tuberculosis impact on HIV reservoir clearance. The research examines how tuberculosis disease affects HIV-1 latent reservoirs in people living with HIV. The study will recruit 200 people with HIV, half with active tuberculosis disease, and follow them for up to 18 months....
- The National Institute of Allergy and Infectious Diseases awarded the University of Massachusetts Medical School $460,625 on February 9, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate immune mechanisms underlying BCG vaccine protection against tuberculosis. The research uses Collaborative Cross mouse strains to identify immune signatures associated with vaccine-induced TB protection across genetically diverse host populations. The study focuses on a...